BioSpace News Archive

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain institutional investors for the sale of an aggregate of 2,418,322 series A units (“Series A Units”) and series B units (“Series B Units” and together with the Series A Units, the “Units”) at a price of US$4.1351 per Series A Unit and US$4.135 per Series B Unit

ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, MD, the Company’s Chief Executive Officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference.

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson*

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 38th Annual J.P. Morgan Healthcare Conferenc

Abbott will announce its fourth-quarter 2019 financial results on Wednesday, Jan. 22, 2020, before the market opens.

Global health service company Cigna (NYSE: CI) announced today that David Cordani, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020 in San Francisco, CA.

DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate plaque psoriasis.

CyberLink Corp. (5203.TW), a pioneer of AI and facial recognition technologies, announced that its FaceMe® AI facial recognition engine has been integrated with iMedtac’s Automatic Dispensing Cabinet.

On January 2nd, the Psomagen-Macrogen Consortium announced the acquisition of all key assets of US company uBiome.

Urology of Virginia announces effective January 1, 2020 the transition of Dr. Joshua Langston to the role of Chief Medical Officer. He will be continuing the legacy of excellent patient care, organizational guidance, innovation and service of his predecessor, Dr. Edwin Robey.